Global Collaborative R&D Partnering Terms and Deals, Leading Companies, Executive Summary, and Scope Until 2019

Posted on 2019-04-03 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Apr-03 — /EPR Network/ —Market Research Hub (MRH) has added a new research study titled “Global Collaborative R&D Partnering Terms and Agreements” in Pharma, Biotech & Diagnostics 2014-2019 which provides all-inclusive understanding as well as unparalleled access to the Collaborative R&D Partnering deals and agreements abided by the leading companies functioning in the pharma, biotech and diagnostics sector. Readers can access in-depth information about the latest Collaborative R&D Partnering agreements together with fully revised and updated versions which can be referred without any hassle. In addition, knowledge about deal term financials and agreement structure is carefully enclosed in this report for the period until 2019.

Get Sample Copy of this Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2222638

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the world’s leading life science companies.

This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2014 to 2019.

There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.

There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all collaborative R&D deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms were available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2014, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2014 where a contract document is available. Each deal title links via Web link to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

Request Report TOC @ https://www.marketresearchhub.com/report/global-collaborative-randd-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2014-2019-report.html

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in collaborative R&D deal making
2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2014
2.6.1. Collaborative R&D deal making by year, 2014 to 2019
2.6.2. Collaborative R&D deal making by phase of development, 2014 to 2019
2.6.3. Collaborative R&D deal making by industry sector, 2014 to 2019
2.6.4. Collaborative R&D deal making by therapy area, 2014 to 2019
2.6.5. Collaborative R&D deal making by technology type, 2014 to 2019
2.6.6. Collaborative R&D deal making by most active company, 2014 to 2019
2.7. The future of collaborative R&D deals

Chapter 3 Overview of collaborative R&D deal structure
3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals

Continued………..@@#

Enquire about This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2222638

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick